Biologic Drugs & Bioprocessing

Complex biologic medicines depend on specialized discovery, manufacturing and quality control, creating barriers beyond ordinary pharmaceutical production. This basket pairs antibody, protein and RNA medicine developers with a supplier of bioprocessing tools. Against a weak technology tape, the theme offers exposure to medical demand rather than AI infrastructure spending, while retaining clinical, reimbursement and manufacturing risks. Launch basket (equal weight): ABBV, AMGN, LLY, MRK, MRNA, TMO, REGN, NVO, ALNY, BMRN Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.